Condition: Muscle-Invasive Bladder Carcinoma · Gastroesophageal Adenocarcinoma · Melanoma · Sponsor: Washington University School of Medicine
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
This description comes directly from the study's public registry record.
William Gillanders, M.D. · 314-747-0072 · gillanders@wustl.edu
Always discuss trial participation with your own doctor first.
| AdventHealth | Orlando, Florida, United States | Not Yet Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06529822